Pharma Foods International (2929) FY2026 Q2 Earnings Report

Quick View

Executive Summary

Although revenue increased, the most important point in these results is that operating income fell from the black into a substantial loss due to a sharp increase in SG&A expenses, primarily advertising and promotional expenses. Revenue was ¥324.4B (+8.7% YoY), operating income was ¥-23.6B (a deterioration of ¥-29.8B from ¥6.2B in the previous year), ordinary income was ¥-24.4B (¥6.5B in the previous year), and interim net income attributable to owners of the parent was ¥-18.2B (¥2.3B in the previous year). The gross margin remained almost flat YoY at 81.1%, indicating that the primary cause of the deterioration in profitability was not cost of sales, but the expansion of SG&A expenses accompanied by a sharp increase in the advertising and promotional expense ratio.

Factors Affecting Business Performance

【Revenue】Revenue of ¥324.4B represented an 8.7% increase YoY. While the core BToC Business led overall growth at ¥287.3B (+10.7%), the BToB Business contracted to ¥35.8B (-4.9%), and the Biomedical Business decreased to ¥1.0B (-23.0%). The composition of the revenue increase indicates a growing concentration in the BToC Business.

【Profit and Loss】Operating income fell to ¥-23.6B (¥6.2B in the previous year). The gross margin was largely maintained at 81.1% (81.3% in the previous year), but SG&A expenses increased 21.1% YoY to ¥286.6B, causing the SG&A ratio to deteriorate by approximately 9.1pt to 88.3% (79.2% in the previous year). Advertising and promotional expenses in particular amounted to ¥214.6B, or 66.2% of revenue (58.4% in the previous year), an increase of approximately 7.8pt, making this the largest factor behind the deterioration in operating results. Segment profit and loss for the BToC Business deteriorated from a profit of ¥+9.9B in the previous year to a loss of ¥-15.6B, as the burden of advertising investment exceeded the contribution from the increase in revenue and pressured earnings. The Company recorded extraordinary losses of ¥1.2B, including losses on the sale of shares in subsidiaries, resulting in a loss before tax of ¥25.5B. After deducting income taxes of ¥-7.3B, interim net loss was ¥18.2B. These results represent an increase in revenue but a substantial decrease in profit, with the Company falling into an operating loss.

Segment Analysis

The BToC Business, with revenue of ¥287.3B (+10.7% YoY), is the core segment, accounting for 88.6% of total revenue. However, segment profit and loss shifted from a profit of ¥+9.9B in the previous year to a loss of ¥-15.6B, resulting in a margin of -5.4%. Although the BToB Business experienced a revenue decline, it secured segment profit of ¥5.0B, representing a margin of 14.0%, and became the largest segment in terms of earnings contribution. The Biomedical Business recorded revenue of ¥1.0B (-23.0%) and a segment loss of ¥2.6B, with profitability deteriorating to -250.0%. Adjustments for company-wide expenses and other items amounted to ¥-10.3B (¥-8.6B in the previous year), including ¥0.2B in amortization of goodwill. Recovery in the profitability of the BToC Business, which led the revenue growth, is the most important issue for a turnaround in consolidated performance.

Key Financial Indicators

【Profitability】Both the operating margin of -7.3% (2.1% in the previous year) and net profit margin of -5.6% (0.8% in the previous year) deteriorated, while the gross margin remained at a high level of 81.1% (81.3% in the previous year). R&D expenses were ¥6.9B, or 2.1% of revenue.【Cash Quality】Operating Cash Flow (OCF) was ¥-27.8B (¥0.2B in the previous year), with an increase in inventories of ¥13.9B and income taxes paid of ¥14.3B serving as sources of cash outflow. Free cash flow was ¥-33.2B, and capital expenditures of ¥4.7B continued within investing cash flow of ¥-5.4B.【Investment Efficiency】Annualized ROE was -37.3%, primarily because both operating results and net income were in the red.【Financial Soundness】The equity ratio declined to 30.3% (35.4% in the previous year), total assets were ¥322.6B, and net assets contracted to ¥97.7B (¥115.5B in the previous year). With current assets of ¥223.4B versus current liabilities of ¥216.7B, working capital is limited, while short-term borrowings of ¥139.0B account for the central portion of interest-bearing debt.

Cash Flow Analysis

OCF was ¥-27.8B, a substantial deterioration from ¥0.2B in the previous year, and free cash flow, including investing cash flow of ¥-5.4B (of which capital expenditures were ¥4.7B), amounted to ¥-33.2B. The primary causes of the deterioration in OCF were the operating loss, as well as cash consumption from a ¥13.9B increase in inventories and ¥14.3B in income taxes paid. A ¥6.8B decrease in trade receivables partially offset these as a source of cash inflow. Financing cash flow was an inflow of ¥18.5B, primarily reflecting an increase in short-term borrowings, resulting in a structure in which the operating deficit and negative FCF were covered through short-term borrowings. Cash and cash equivalents declined, with the balance at the end of the period falling below the balance at the end of the previous fiscal year. The fact that inventories increased by more than 22% from the previous year requires ongoing monitoring from the perspectives of the pace of inventory sales and the tie-up of funds.

Quality of Earnings

The deterioration in results during the current period was attributable to a sharp increase in advertising and promotional expenses, which are recurring business operating costs, while the impact of temporary factors was relatively small. Extraordinary losses of ¥1.2B, including losses on the sale of shares in subsidiaries, are distinguished as non-recurring factors outside ordinary operations. However, extraordinary gains and losses had only a limited impact on the loss before tax of ¥25.5B, and the fundamental cause of the deterioration lies in the SG&A expense structure at the operating level. Non-operating income, including dividends received, was ¥1.6B, while non-operating expenses, including commissions paid and interest expenses, were ¥2.4B. The net non-operating loss of ¥-0.8B was insufficient to offset the operating deficit. Comprehensive income was ¥-16.0B, and the difference from net income of ¥-18.2B was attributable to a ¥2.2B increase in valuation difference on securities. The divergence between the two was limited. Although the accrual ratio, in which OCF exceeds net income, was small, OCF itself was substantially negative, and the Company cannot be viewed as having a strong ability to convert earnings into cash.

Earnings Forecast and Guidance

The full-year earnings forecast is revenue of ¥670.0B (+2.7% YoY), operating income of ¥20.0B (-15.5%), and ordinary income of ¥20.0B (-21.7%), and the earnings forecast was revised during the current quarter. While cumulative first-half revenue progress was 48.4%, nearly in line with the plan, operating income was a loss of ¥23.6B. Accordingly, achieving the full-year plan of ¥20.0B will require an improvement of approximately ¥43.6B in operating income during the second half. Against the net income forecast of ¥15.0B, the Company recorded a first-half loss of ¥18.2B, making a substantial earnings turnaround in the second half a prerequisite for the forecast.

Shareholder Returns

The Q2 (interim) dividend was ¥12.5 per share, and the full-year dividend forecast remains unchanged at ¥25.0 per share. As a dividend was paid despite interim net loss of ¥18.2B, the payout ratio for the interim period is not meaningful because net income was negative. Based on the forecast total dividend corresponding to the full-year net income forecast of ¥15.0B (calculated using ¥25.0 per share), the expected payout ratio is approximately 48%. However, first-half actual results were substantially below the full-year plan, and the sustainability of the dividend will depend on earnings recovery in the second half. As both OCF and free cash flow were negative, the interim dividend depended not on internally generated funds, but on cash on hand or borrowing capacity.

Risk Factors

1. Risk of recovering advertising investment in the BToC Business: BToC revenue increased 10.7% YoY to ¥287.3B, but segment profit and loss deteriorated from ¥+9.9B in the previous year to ¥-15.6B. Advertising and promotional expenses rose to 66.2% of revenue, and if repeat customer purchases or profitability improvements are delayed, losses could persist over an extended period.

2. Dependence on short-term borrowings and changes in the funding structure: Short-term borrowings increased ¥25.0B YoY to ¥139.0B, while long-term borrowings decreased to ¥3.9B. The Company is covering free cash flow of ¥-33.2B through short-term borrowings, making the continued availability of refinancing an important aspect of its cash management.

3. Rising inventory levels: Inventories increased ¥14.2B YoY to ¥77.3B. This increase exceeded the pace of revenue growth (+8.7%), and if delays in inventory sales occur, the Company may incur valuation losses or experience additional funds being tied up.

Industry Benchmark (For Reference; Company Research)

Profitability and Return

As comparative data within the industry is limited, the Company’s positioning is based solely on its own figures; both profit and loss remain in the loss range.

Growth and Capital Efficiency

Although revenue growth itself has been secured, when viewed together with profitability indicators, the results suggest challenges in the quality of the revenue increase.

Source: Company research

Key Points of the Results

1. Although revenue has increased for 8 consecutive periods, operating income shifted from a profit in the previous year to a loss in the current period, confirming a structural change in which revenue growth has not translated into earnings growth. As the gross margin has remained in the 81% range, the focus of the deterioration in profitability is the efficiency of SG&A expenses, particularly advertising and promotional expenses.

2. By segment, the BToC Business accounts for more than 80% of revenue but has become a loss-making segment, while the BToB Business has become the core contributor to profit. The imbalance in the earnings structure within the business portfolio is a structural inflection point that will determine the quality of future consolidated performance.

3. The full-year company forecast assumes a substantial shortfall in the first half and incorporates an earnings turnaround in the second half. Progress against the plan and the pace at which advertising investment is recovered will therefore be key points of focus in future results.

Theoretical Share Price (Reference Value)

Sensitivity: ¥391–¥414 at cost of equity ±1%, and ¥401–¥404 at ω±0.1.

Notes:

• Goodwill amortization of ¥1.2 per share has been added back to earnings (due to its non-cash nature and for comparability with IFRS companies).
• Net assets as of the quarter-end have been used (there is a time lag relative to the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---